MNTA: The delay with the decision is typical of the FDA. I'm not attributing a decrease in the chances of approval to a longer and longer delay. If anything the more stringent the FDA is the more likely MNTA is the sole generic for the foreseeable future.
The importance and value of MNTA will soon become more visible to the investing community once we get the cascade of probable events- m-enox, M356, M118 partnership, FOB partnerships.
I expect MNTA to really take off with many FOB partnerships announced by the end of the year/early 2011. I'm sure MNTA hasn't been sitting on their hands waiting for M-enox approval.
Market Data 
Markets 
AI
